Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

The OncFive: Top Oncology Articles for the Week of 12/15


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Novel Breakthroughs in Management of Pediatric Low-Grade Glioma (pLGG)

Clinical

Video Series

Radiation and Targeted Therapies for Progressive pLGG

Please briefly describe the various treatment options that might be considered in R/R pLGG

Videos

Pediatric low-grade glioma specialists examine recent therapeutic advancements and their practical implications, presenting two real-world cases to demonstrate the integration of new data into clinical decision-making.

Key opinion leaders offer a comprehensive overview of pediatric low-grade glioma, encompassing its epidemiology, characteristic disease presentation, differentiation from adult manifestations, and impact on patients' quality of life.

Overview of pLGG presentation and categorization

Experts examine the molecular diversity of pediatric low-grade gliomas, exploring its significance for diagnostic approaches and therapeutic strategies.

Molecular Characterization of pLGG

The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.

Less Common Molecular Alterations in pLGG and Testing Recommendations

The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current best practices and therapeutic approaches.

Standard of care for frontline treatment of non-V600E-specific pLGG tumors

The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.

Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

Current Treatment of Patients with NF1 pLGG

The panel explores the standard of care options tailored specifically for the frontline treatment of pediatric low-grade gliomas (pLGG) harboring the BRAF V600E mutation, discussing current best practices and targeted therapeutic approaches.

Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

Treatment Considerations for Progressive pLGG

The panel of medical experts examines the roles of radiation therapy and targeted therapies in the management of progressive pediatric low-grade gliomas (pLGG).

The panel reviews ongoing clinical trials aimed at expanding treatment options for progressive pediatric low-grade gliomas (pLGG), with a specific focus on the PNOC021, PBTC-055, and NF111 studies, discussing their objectives, design features, and potential impact on future treatment strategies.

The Role of Tovorafenib in Treatment of Progressive pLGG

Clinical Trials to Increase Treatment Options in the Progressive Setting

The panel examines a specific patient case, offering detailed insights into their decision-making process and treatment approaches for patients with pediatric low-grade gliomas (pLGG).

Clinical scenario 1 - BRAFKIAA-1549 fusion

The panel presents alternative treatment options and key considerations for the discussed clinical scenario, elaborating on the factors that influence their decision-making process.

Alternatives and Considerations for Clinical Scenario 1

The key opinion leaders analyze a second clinical scenario, focusing on a patient with a BRAF V600E mutation in their pediatric low-grade glioma (pLGG).

Clinical Scenario 2 - BRAFV600E

The panel of pediatric low-grade glioma (pLGG) experts delves into the potential adverse events associated with targeted therapies, outlining common reactions and their severity, while also sharing their strategies and best practices for toxicity management.

Potential Adverse Events With Targeted Therapies

The leaders in the pediatric low-grade glioma (pLGG) field offer their concluding insights and perspectives on the future of pLGG management.

Radiation and Targeted Therapies for Progressive pLGG

EP: 1.Overview of pLGG presentation and categorization

EP: 2.Molecular Characterization of pLGG

EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations

EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors

EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

EP: 6.Current Treatment of Patients with NF1 pLGG

EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

EP: 8.Treatment Considerations for Progressive pLGG

EP: 9.Radiation and Targeted Therapies for Progressive pLGG

EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG

EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting

EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion

EP: 13.Alternatives and Considerations for Clinical Scenario 1

EP: 14.Clinical Scenario 2 - BRAFV600E

EP: 15.Potential Adverse Events With Targeted Therapies

EP: 16.Clinical Insights: Looking Forward for pLGG

Latest Conference Coverage